Microscopic detection of blast-transformed mononuclear cells
AssigneeImmunogenetics.Com, Inc.
InventorRobert Michael Williams
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for determining prognosis of cancer and/or infection in a subject based on the number of viable blast-transformed mononuclear cells and/or the number of viable large granular lymphocytes in a blood sample obtained from the subject.
Claims28
A method of determining prognosis of cancer or infection in a subject, the method comprising:
- (a) contacting a blood sample obtained from the subject with a cell viability dye;
- (b) after step (a), generating a microscopic slide using the blood sample;
- (c) identifying a number of viable blast-transformed mononuclear cells and/or a number of viable large granular lymphocytes in the microscopic slide using microscopic analysis;
- and
- (d) identifying a subject having an increased number of viable blast-transformed mononuclear cells and/or an increased number of viable large granular lymphocytes, as compared to a reference level, as having an improved prognosis of cancer or infection;
- or
- identifying a subject having a decreased number of viable blast-transformed mononuclear cells and/or a decreased number of viable large granular lymphocytes, as compared to a reference level, as having a poor prognosis of cancer or infection.
(canceled)
-10. (canceled)
(canceled)
(canceled)
-25. (canceled)
-28. (canceled)
A method of selecting a treatment for a subject not identified or diagnosed as having cancer or infection, the method comprising:
- (a) contacting a blood sample obtained from the subject with a cell viability dye;
- (b) after step (a), generating a microscopic slide using the blood sample;
- (c) identifying a number of viable blast-transformed mononuclear cells and/or a number of viable large granular lymphocytes in the microscopic slide using microscopic analysis;
- (d) identifying a subject having an increased number of viable blast-transformed mononuclear cells and/or an increased number of viable large granular lymphocytes, as compared to a reference level, as having an improved prognosis of cancer or infection;
- or identifying a subject having a decreased number of viable blast-transformed mononuclear cells and/or a decreased number of viable large granular lymphocytes, as compared to a reference level, as having a poor prognosis of cancer or infection;
- and
- (e) selecting for a subject identified as having an improved prognosis of cancer or infection a low frequency of cancer or infection screening for the subject, or selecting for a subject identified as having a poor prognosis of cancer or infection a high frequency of cancer or infection screening for the subject.
-58. (canceled)
A method of treating a subject not identified as having cancer or infection, the method comprising:
- (a) contacting a blood sample obtained from the subject with a cell viability dye;
- (b) after step (a), generating a microscopic slide using the blood sample;
- (c) identifying a number of viable blast-transformed mononuclear cells and/or a number of viable large granular lymphocytes in the microscopic slide using microscopic analysis;
- (d) identifying a subject having an increased number of viable blast-transformed mononuclear cells and/or an increased number of viable large granular lymphocytes, as compared to a reference level, as having an improved prognosis of cancer or infection;
- or identifying a subject having a decreased number of viable blast-transformed mononuclear cells and/or a decreased number of viable large granular lymphocytes, as compared to a reference level, as having a poor prognosis of cancer or infection;
- and
- (e) performing low frequency cancer or infection screening on a subject identified as having an improved prognosis of cancer or infection, or performing high frequency cancer or infection screening on a subject identified as having a poor prognosis of cancer or infection.
-86. (canceled)
Dependencies are inferred from the claim text.